Dr Adam H Althoff, PHARM D in San Lenadro, CA - Pharmacist

Dr Adam H Althoff, PHARM D is a Pharmacist based in San Lenadro, California. Dr Adam H Althoff is licensed to practice in California (license number 40722) and his current practice location is 2500 Merced Street, San Lenadro, California. He can be reached at his office (for appointments etc.) via phone at (510) 454-1000.

NPI number for Dr Adam H Althoff is 1518010123 and his current mailing address is 2500 Merced St, San Leandro, California. He does not participate in medicare program and thus does not accept medicare assignments. His NPI Number is 1518010123.

Contact Information

	Dr Adam H Althoff, PHARM D
	2500 Merced Street, San Lenadro, CA 94577-4201
	(510) 454-1000
	Not Available

Healthcare Provider's Profile

Full Name	Dr Adam H Althoff
Gender	Male
Speciality	Pharmacist
Location	2500 Merced Street, San Lenadro, California
Accepts Medicare Assignments	Does not participate in Medicare Program. He may not accept medicare assignment.

NPI Data:

NPI Number: 1518010123
Provider Enumeration Date: 01/18/2007
Last Update Date: 11/24/2021

Medical Identifiers

Medical identifiers for Dr Adam H Althoff such as npi, medicare ID, medicare PIN, medicaid, etc.

Identifier	Type	State	Issuer
1518010123	NPI	-	NPPES

Medical Taxonomies and Licenses

Taxonomy	Type	License (State)	Status
183500000X	Pharmacist	40722 (California)	Primary

Medicare Part D Prescriber Enrollment

Any physician or other eligible professional who prescribes Part D drugs must either enroll in the Medicare program or opt out in order to prescribe drugs to their patients with Part D prescription drug benefit plans. Dr Adam H Althoff is NOT enrolled with medicare and thus cannot prescribe medicare part D drugs to patients with medicare part D benefits.

Mailing Address and Practice Location

Mailing Address	Practice Location Address
Dr Adam H Althoff, PHARM D 2500 Merced St, San Leandro, CA 94577-4201 Ph: (510) 454-1000	Dr Adam H Althoff, PHARM D 2500 Merced Street, San Lenadro, CA 94577-4201 Ph: (510) 454-1000

News Archive

Novartis' JUMP study reinforces safety, efficacy of Jakavi (ruxolitinib) for myelofibrosis treatment

Novartis today announced data from the largest clinical trial of myelofibrosis patients treated with Jakavi (ruxolitinib), supporting the safety profile and efficacy benefit as measured in primary and secondary endpoints respectively.

Advancements in the Optimization of Medical Accelerators

Radiotherapy is a way of treating cancer by means of radiation. In principle, that can be all different types of radiation. The commonly known types are X-rays or electron beams, which find very widespread application.

Riluzole ‘a candidate treatment' for cerebellar ataxia

Riluzole may be an effective treatment for cerebellar ataxia, say researchers who call for further studies to confirm their findings.

Mylan receives FDA approval for generic Seroquel ANDA

Mylan Inc. today announced that its subsidiary Mylan Pharmaceuticals Inc. has received final approval from the U.S. Food and Drug Administration (FDA) for its Abbreviated New Drug Application (ANDA) for Quetiapine Fumarate Tablets, 25 mg.

Reducing use of 'low value' surgical procedures vital to cut healthcare costs and enhance care

Reducing the use of 'low value' interventions that deliver little benefit is vital to cut healthcare costs. In the BJS, investigators have identified 71 low value general surgical procedures, of which five services were of high volume and high cost, 23 were of high cost and low volume, 22 belonged to the low cost and high volume group, and 21 were in the low cost and low volume group.

Dr Adam H Althoff, PHARM D - Pharmacist in San Lenadro, CA